The present study was designed, therefore, to investigate the role of APCR or ATR in VTEs induced by the concomitant use of emicizumab and APCCs in persons with hemophilia A. Thrombin generation assays (TGAs) were used to assess APCR and ATR in pooled normal plasma (PNP) and in FVIII-deficient (FVIIIdef) plasma in the presence of emicizumab and APCCs. This evidence concerns the gene F8 and hemophilia A.